Recombinant Mouse Trefoil Factor 1/TFF1 Protein (His Tag)

Catalog Number: PKSM041269

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description			
Species	Mouse		
Source	HEK293 Cells-derived Mouse Trefoil Factor 1/TFF1 protein Gln22-Phe87, with an C-		
	terminal His		
Calculated MW	8.3 kDa		
Observed MW	15 kDa		
Accession	Q08423		
Bio-activity	Not validated for activity		
Properties			
Purity	> 95 % as determined by reducing SDS-PAGE.		
Endotoxin	< 1.0 EU per µg of the protein as determined by the LAL method.		
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80		
	°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of		
	reconstituted samples are stable at $< -20^{\circ}$ C for 3 months.		
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.		
Formulation	Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4.		
	Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants		
	before lyophilization.		
	Please refer to the specific buffer information in the printed manual.		
Reconstitution	Please refer to the printed manual for detailed information.		

Data

kDa	MK	R
120 90 60 40		
30	-	
20	-	
14	-	-
		Station of the

Background

Elabscience®

Trefoil Factor 1 (TFF1) belongs to the three structurally related secreted proteins that contain trefoil domains.TFF1 is an approximately peptide that has an important effect in epithelial regeneration and wound healing.It originates from musculus and highly expressed by goblet cells of the gastric and intestinal mucosa and by conjunctival goblet cells. TFF1 is a copper-binding protein that can form disulfide-linked homodimers, associate into disulfide-linked complexes with Gastrokine 2, and form non-covalent complexes with the mucin MUC5AC. TFF1 is down-regulated during the progression from gastritis to gastric dysplasia to gastric cancer, although it is up-regulated in breast and prostate cancers. TFF1 inhibits the formation of calcium oxalate crystals, and its excretion in the urine is reduced in patients with kidney stones.